Journal
CELL HOST & MICROBE
Volume 27, Issue 6, Pages 870-878Publisher
CELL PRESS
DOI: 10.1016/j.chom.2020.05.008
Keywords
-
Categories
Funding
- NIH [1R01AI127429, 75N93019C00051, 1R01NS111242, 2U19AI089992]
- Women's Health Research at Yale Pilot Project Program, Emergent Ventures at the Mercatus Center, George Mason University
- Mathers Foundation
- Ludwig Family Foundation
Ask authors/readers for more resources
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available